SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Show more

1 Evertrust Plaza, Jersey City, NJ, 07302-6548, United States

Drug Manufacturers - Specialty & Generic

Healthcare

Market Cap

38.36M

52 Wk Range

$0.56 - $1.31

Previous Close

$0.86

Open

$0.87

Volume

418,268

Day Range

$0.86 - $0.96

Enterprise Value

501.3K

Cash

37.93M

Avg Qtr Burn

-8.724M

Insider Ownership

3.49%

Institutional Own.

27.89%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Brexafemme (Ibrexafungerp) Details Vulvovaginal Candidiasis, Yeast Infection	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Brexafemme (Ibrexafungerp) Details Fungal infections	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SCY-247 Details Fungal infections	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SCY-078 Details Invasive Candidiasis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.